{"doc_desc":{"title":"French cystic fibrosis register (qualified register)","idno":"FRESH-PEF219-en","producers":[{"name":"Virginie COLOMB-JUNG","affiliation":"VAINCRE LA MUCOVISCIDOSE (AFLM)"}]},"study_desc":{"title_statement":{"idno":"FRESH-PEF219-en","IDno":{"metadata_no":[{"agency":"PEF","code":"219"},{"agency":"FReSH","code":"FRESH-PEF219"}]},"title":"French cystic fibrosis register (qualified register)","alternate_title":""},"study_authorization":{"agency":[]},"authoring_entity":[{"name":"Gilles;RAULT","firstname":"Gilles","lastname":"RAULT","type":"investigator","extlink":[{"title":"","uri":"","role":"organisation id"}],"email":"gilles.rault@ildys.org","affiliationName":"chu","PILabo":"CHU \/ Centre de r\u00e9f\u00e9rence de la mucoviscidose","isContact":true},{"name":"Virginie;COLOMB-JUNG","firstname":"Virginie","lastname":"COLOMB-JUNG","type":"investigator","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/00gp9bw49","role":"organisation id"},{"title":"SIREN","uri":"784287583","role":"organisation id"}],"email":"vcolomb@vaincrelamuco.org","affiliationName":"VAINCRE LA MUCOVISCIDOSE (AFLM)","PILabo":"Association Vaincre la Mucoviscidose","isContact":true}],"oth_id":[{"name":""}],"production_statement":{"prod_place":"Epidemiology France Portal (PEF)","producers":[{"name":"VAINCRE LA MUCOVISCIDOSE (AFLM)","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/00gp9bw49","role":"sponsor id"},{"title":"SIREN","uri":"784287583","role":"sponsor id"}],"role":"sponsor"}],"funding_agencies":[{"name":"CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/05c1qsg97"},{"title":"SIREN","uri":"264400136"}]},{"name":"INSTITUT NATIONAL D'ETUDES DEMOGRAPHIQUES (INED)","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/02cnsac56"},{"title":"SIREN","uri":"180037020"}]},{"name":"VAINCRE LA MUCOVISCIDOSE (AFLM)","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/00gp9bw49"},{"title":"SIREN","uri":"784287583"}]}]},"distribution_statement":{"contact":[{"name":"Gilles;RAULT","lastname":"RAULT","firstname":"Gilles","type":"contact","email":"gilles.rault@ildys.org","affiliationName":"chu","contactPointLabo":"","extlink":[]},{"name":"Virginie;COLOMB-JUNG","lastname":"COLOMB-JUNG","firstname":"Virginie","type":"contact","email":"vcolomb@vaincrelamuco.org","affiliationName":"VAINCRE LA MUCOVISCIDOSE (AFLM)","contactPointLabo":"","extlink":[{"uri":"https:\/\/ror.org\/00gp9bw49","role":"organisation id","title":"ROR"},{"uri":"784287583","role":"organisation id","title":"SIREN"}]}]},"study_info":{"keywords":[],"topics":[{"topic":"Pulmonary medicine","vocab":"health theme","extLink":[{"title":"ESV","uri":"http:\/\/data.europa.eu\/8mn\/euroscivoc\/f6e18c52-6087-4662-904c-5c4b8174e40e"},{"title":"MeSH","uri":"http:\/\/id.nlm.nih.gov\/mesh\/D015272"}]},{"topic":"Cystic fibrosis","vocab":"cim-11","extLink":[{"uri":"http:\/\/id.who.int\/icd\/entity\/514403112","title":"CIM-11"}]},{"topic":"Biological determinants: Genetic predisposition","vocab":"health determinant"},{"topic":"Biological determinants","vocab":"health determinant"}],"purpose":"1) Descriptive and analytical epidemiology \u2022 Estimate the prevalence, incidence, geographical distribution and number of patients suffering from cystic fibrosis in France \u2022 Estimate mortality and life expectancy at different ages \u2022 Determine the mortality risk factors \u2022 Describe the medical and socio-demographic characteristics of the population, especially elements concerning diagnosis, anthropometry, spirometry, microbiology, morbidity, transplants and treatment, as well as the educational and professional situations of patients. The descriptive analysis of this data is finalized by the publication of an annual report and center reports and is subject to other publications, posters, communication during congresses and information given to families and patients via the association's magazine. 2) Evaluation of healthcare practices The data is used to evaluate the quality of treatment, health care and diagnosis of cystic fibrosis. It also provides responses to the fundamental question on equity in these three fields, by comparing these practices to the national diagnosis and care protocol for this rare disease. The following is also carried out: \u2022 analysis of survival factors by introducing the treatment location and type of caring for example, in addition to the traditional variables. \u2022 evaluation of the socioeconomic cost of cystic fibrosis by trying to match resources to the constantly changing needs. \u2022 evaluation of neonatal screening (Cazes et al, ECFS 2005) \u2022 development of a Program for Improving the Quality of cystic fibrosis health care by looking to the benchmarks extracted from the registry (mainly the FEV1 and BMI). 3) The registry's objectives in the fields of therapy and research \u2022 Provision of a database for physicians and researchers. \u2022 Search for genotype-phenotype correlations (Dugu\u00e9p\u00e9roux et al, 2002, 2004, 2005). \u2022 Setup of thematic surveys, for example: \u2022 \"Pregnancy\" survey: an initial stage has consisted in a retrospective study of pregnancies listed in France between 1980 and 1995. At the end of this study, a prospective registry was set up in 1996 under the observatory, involving an additional questionnaire for any pregnancy reported in the observatory's data collection. The retrospective study and first few years of prospective data collection led to a publication (Gillet et al, 2002). \u2022 Cross-disciplinary study on \"transplants\" conducted in 2000 in liaison with the French Biomedicine Agency. In addition to the findings, it determined a number of important variables to collect and integrate into the registry. \u2022 \"Cepacia\" survey: the Cepacia observatory was set up in 1993 by the \"Vaincre la Mucoviscidose\" association. Its Scientific Director is Prof. G. Chabanon. This observatory is one of the thematic observatories of the registry, with which it shares some data, including the main characteristics for identifying patients; the Cepacia observatory networks with clinicians and microbiologists in healthcare centers. Its remit involves, on the one hand, conducting epidemiological surveillance of colonizations and infections by Burkholderia cepacia complex and similar bacteria in cystic fibrosis sufferers; on the other hand, building a national reference strain bank for use by the scientific community. \u2022 \"Mucoviscidose, Famille et Soci\u00e9t\u00e9\" survey: organized by the French National Institute for Demographic Studies (Ined), Reference Center for Rare Diseases, \"Cystic Fibrosis\", of Nantes teaching hospital and the \"Vaincre la Mucoviscidose\" association. This aims to gather the views of the patients themselves - children, teenagers and adults - of their lifestyles and conditions: What are their family situations? What are their residential, academic and professional pathways? What aspects are linked to social recognition of the disease, and the benefits and help received? What are their possible functional limitations and\/or activity restrictions? How is their social life characterized, how do they perceive the disease and how do they get on with their usual care center? What are their needs, expectations and aspirations? This information gleaned from patients will then be compared against medical data in the French Cystic Fibrosis Registry from the Cystic Fibrosis Skills and Resources Centers (CRCMs). The purpose of this study is to set up a five-year national survey of the Registry, created and managed by the \"Vaincre la Mucoviscidose\" association. The project comprises two stages: firstly a preliminary feasibility stage, when a pilot survey is conducted among patients followed up in the Roscoff and Strasbourg CRCMs; secondly a national survey will be conducted among all of the patients followed up by the CRCMs across France and re-launched every five years.","abstract":"","coll_dates":[{"start":"1992-01-01"}],"nation":[{"name":"France","abbreviation":"fr","extLink":{"vocab":"ISO","vocabURI":"fr"}}],"geog_coverage":"","analysis_unit":"Individuals","universe":"{\n    \"level_sex_clusion_I\": [\n        {\n            \"value\": \"Male\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D008297\"\n            }\n        },\n        {\n            \"value\": \"Female\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D005260\"\n            }\n        }\n    ],\n    \"level_age_clusion_I\": [\n        {\n            \"value\": \"Infant, Newborn (birth to 28 days)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D007231\"\n            }\n        },\n        {\n            \"value\": \"Infant (28 days to 2 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D007223\"\n            }\n        },\n        {\n            \"value\": \"Child, Preschool (2 to 5 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D002675\"\n            }\n        },\n        {\n            \"value\": \"Child (6 to 12 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D002648\"\n            }\n        },\n        {\n            \"value\": \"Young Adult (19 to 24 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D055815\"\n            }\n        },\n        {\n            \"value\": \"Adult (25 to 44 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D000328\"\n            }\n        },\n        {\n            \"value\": \"Middle Aged (45 to 64 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D008875\"\n            }\n        },\n        {\n            \"value\": \"Aged (65 to 79 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D000368\"\n            }\n        }\n    ],\n    \"level_type_clusion_I\": \"Patients population\",\n    \"level_type_clusion_other\": \"\",\n    \"clusion_I\": \"The criteria for inclusion in the registry are - in addition to consent by the patient and\\\/or parents for data to be used - those defined by the 1998 consensus conference of the Cystic Fibrosis Foundation and reported by Rosenstein and Cutting.  These combine clinical and biological criteria:  1) the presence of one or more phenotypic characteristics or a family history of cystic fibrosis among siblings, or an increased rate of immunoreactive trypsin (neonatal screening) and  2) two positive sweat tests, or two mutations identified of the CFTR gene, or a pathological nasal transepithelial potential difference.  This definition of cystic fibrosis is currently being amended in the registry following the recommendations in J Ped 2008:153:S4-S14\",\n    \"clusion_E\": \"\"\n}","data_kind":"['Clinical data','Biological data','Socio-demographic data','Paraclinical data (non-biological) : Function testing']","quality_statement":{"standards":[{"name":"","committee":"","governance":""}],"other_quality_statement":""}},"study_development":{"development_activity":[{"activity_type":"primary evaluation","activity_description":"Health event\/morbidity\r\nHealth event\/mortality\r\nHealth care consumption and services"}]},"method":{"data_collection":{"time_method":"","frequency":"","sampling_procedure":"['{\"concept\":{\"vocabURI\":\"Other\",\"vocab\":\"CESSDA\"},\"value\":\"Other\"}']","sample_frame":{"frame_unit":{"unit_type":""}},"coll_mode":["{\"concept\":{\"vocabURI\":\"Interview\",\"vocab\":\"CESSDA\"},\"value\":\"Interview with the participant (including clinical)\"}"],"research_instrument":"Access on specific project only","sources":[],"target_sample_size":"[1000-10000[ individuals","response_rate":"Number of patients notified since the beginning of the recording year by year: Year : 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Number of patients : 1641 1849 2032 2215 2406 2551 2707 3231 3377 3589 3936 4111 4544 4745 4994 5140 5357 Analysis in progress"},"method_notes":"Observational Study","study_class":"Unknown","notes":[{"subject":"research type","values":["Observational Study"]},{"subject":"observational study method","values":["Morbidity registry"]}]},"data_access":{"dataset_availability":{"access_place":"","complete":"","status":"{\"value\":\"Restricted access\",\"extLink\":[{\"title\":\"COAR\",\"uri\":\"http:\/\/purl.org\/coar\/access_right\/c_16ec\"}]}"},"dataset_use":{"restrictions":"","conditions":"Data demand on : http:\/\/www.vaincrelamuco.org\/ewb_pages\/d\/donnees_registre.php","conf_dec":[{"txt":""}],"spec_perm":[{"txt":"","required":""}],"contact":[{"name":""}],"deposit_req":"","cit_req":""},"notes":""}},"additional":{"IsImport":true,"versionLang":"en","originLang":"en","autoTranslation":false,"status":"imported","creationDate":"27-12-2010","lastUpdatedAuto":null,"lastUpdatedManual":"11-02-2014","isContributorPI":false,"contributorName":"","contributorAffiliation":"","addTeamMember":"","obtainedAuthorization":{"otherAuthorizingAgency":[]},"relatedDocument":[{"type":"","title":"","link":"http:\/\/www.registredelamuco.org"}],"regulatoryRequirements":{"conformityDeclaration":""},"fundingAgent":{"fundingAgentType":["Public (France)","Public (France)","Private non-profit"],"otherFundingAgentType":["","",""]},"sponsor":{"sponsorType":["Private non-profit"],"otherSponsorType":[""]},"governance":{"committee":""},"collaborations":{"networkConsortium":""},"theme":{"complementaryInformation":"","RareDiseases":true},"activeFollowUp":{"isActiveFollowUp":true,"followUpModeOther":""},"interventionalStudy":{"researchPurpose":[],"trialPhase":[],"interventionalStudyModel":"","isClinicalTrial":"","otherResearchPurpose":""},"isInclusionGroups":"","allocation":{"allocationMode":"","allocationUnit":""},"masking":{"maskingType":"","blindedMaskingDetails":[]},"arms":[],"intervention":[],"inclusionGroups":[],"collectionProcess":{"collectionModeDetails":"Annual questionnaires (3 types of collection: import from the patient software, online data entry and paper questionnaire)","collectionModeOther":""},"dataCollection":{"inclusionStrategyOther":"","samplingModeOther":"","recruitmentSourceOther":"","otherDocumentation":""},"dataCollectionIntegration":{"isDataIntegration":false},"geographicalCoverage":{"geoDetail":"Metropolitan France (all the 22 regions) as well as Reunion island"},"dataTypes":{"clinicalDataDetails":"","biologicalDataDetails":"Cytobacteriological sputum examination. Blood gases (SaO2, PaO2, PaCO2)","isDataInBiobank":false,"biobankContent":[],"biobankContentOther":"","dataTypeOther":""},"variableDictionnary":{"variableDictionnaryAvailable":"","variableDictionnaryLink":""},"dataQuality":{"otherDocumentation":""},"mockSample":{"mockSampleAvailable":"","mockSampleLocation":""},"thirdPartySource":{"otherSourceType":[]},"isHealthTheme":true,"fileDscr":{"fileTxt":{"fileCitation":{"titlStmt":{"IDno":[]}}}}},"schematype":"survey"}